3-(5-(2-(1-(3,5-difluorophenyl)cyclohexyl)ethyl)-1,2,4-oxadiazol-3-yl)-6-methy1-2(1H)-pyridinone | 1367347-05-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(5-(2-(1-(3,5-difluorophenyl)cyclohexyl)ethyl)-1,2,4-oxadiazol-3-yl)-6-methy1-2(1H)-pyridinone
• 英文别名: 3-(5-(2-(1-(3,5-difluorophenyl)cyclohexyl)ethyl)-1,2,4-oxadiazol-3-yl)-6-methylpyridin-2(1H)-one；3-[5-[2-[1-(3,5-difluorophenyl)cyclohexyl]ethyl]-1,2,4-oxadiazol-3-yl]-6-methyl-1H-pyridin-2-one
• CAS: 1367347-05-4
• 化学式: C₂₂H₂₃F₂N₃O₂
• 分子量: 399.44
• InChiKey: SLIVNWJPVPUOBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N'-HYDROXY-6-METHYL-2-OXO-1,2-DIHYDRO-3-PYRIDINECARBOXIMIDAMIDE 、 3-(1-(3,5-difluorophenyl)cyclohexyl)propanoic acid 在 N,N'-二异丙基碳二亚胺 、 四丁基氟化铵 作用下， 以 乙腈 为溶剂， 反应 146.5h， 以26.7%的产率得到3-(5-(2-(1-(3,5-difluorophenyl)cyclohexyl)ethyl)-1,2,4-oxadiazol-3-yl)-6-methy1-2(1H)-pyridinone
  参考文献：
  名称：

  [EN] SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS
  [FR] COMPOSÉS OXADIAZOLES SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'AGONISTES DU S1P1

  摘要：

  公开了式(I)的化合物：[请在此处插入化学结构]或其立体异构体、N-氧化物、盐或前药；其中：环A是苯基或5至6元杂芳基；(i) R1和R2各自独立地是C1-C4烷基；或(ii) R1和R2与其所连接的碳原子一起形成一个环状基团；Q是带有零至3个取代基的苯基或5至6元杂芳基；并且R3、L1、L2和n如本文所定义。还公开了使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓各种治疗领域中的疾病或障碍的进展方面有用，例如自身免疫性疾病和血管疾病。

  公开号：

  WO2012040532A1

文献信息

• SUBSTITUTED OXADIAZOLE COMPOUNDS
  申请人：Das Jagabandhu

  公开号：US20130190361A1

  公开（公告）日：2013-07-25

  Disclosed are compounds of Formula (I): or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl; or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; Q is phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents; and R3, L1, L2, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及以下式(I)的化合物或其立体异构体、N-氧化物、盐或前药： 其中：环A是苯基或5-至6-成员杂环基； (i) R1和R2独立地是C1-C4烷基；或 (ii)R1和R2与它们连接的碳原子一起形成一个环状基团； Q是苯基或5-至6-成员杂环基，其被0-3个取代基取代；R3、L1、L2和n的定义详见说明书。 本发明还涉及将这些化合物用作选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在多种治疗领域中用于治疗、预防或减缓疾病或障碍的进展，如自身免疫性疾病和血管疾病。
• Substituted oxadiazole compounds
  申请人：Das Jagabandhu

  公开号：US09187437B2

  公开（公告）日：2015-11-17

  Disclosed are compounds of Formula (I): or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl; or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; Q is phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents; and R3, L1, L2, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及公式（I）的化合物：或其立体异构体，N-氧化物，盐或前药；其中：环A是苯基或5-至6-成员杂环基；（i）R1和R2独立地为C1-C4烷基；或（ii）R1和R2与它们所附着的碳原子一起形成一个环状基团；Q是苯基或5-至6-成员杂环基，其被零到3个取代基取代；R3，L1，L2和n在此定义。本发明还涉及使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这种化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或障碍方面非常有用，例如自身免疫疾病和血管疾病。
• SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2619190A1

  公开（公告）日：2013-07-31
• US9187437B2
  申请人：——

  公开号：US9187437B2

  公开（公告）日：2015-11-17
• [EN] SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS<br/>[FR] COMPOSÉS OXADIAZOLES SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'AGONISTES DU S1P1
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012040532A1

  公开（公告）日：2012-03-29

  Disclosed are compounds of Formula (I): [PLEASE INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl; or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; Q is phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents; and R3, L1, L2, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  公开了式(I)的化合物：[请在此处插入化学结构]或其立体异构体、N-氧化物、盐或前药；其中：环A是苯基或5至6元杂芳基；(i) R1和R2各自独立地是C1-C4烷基；或(ii) R1和R2与其所连接的碳原子一起形成一个环状基团；Q是带有零至3个取代基的苯基或5至6元杂芳基；并且R3、L1、L2和n如本文所定义。还公开了使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓各种治疗领域中的疾病或障碍的进展方面有用，例如自身免疫性疾病和血管疾病。